EP1784406A1 - Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments - Google Patents
Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicamentsInfo
- Publication number
- EP1784406A1 EP1784406A1 EP05779168A EP05779168A EP1784406A1 EP 1784406 A1 EP1784406 A1 EP 1784406A1 EP 05779168 A EP05779168 A EP 05779168A EP 05779168 A EP05779168 A EP 05779168A EP 1784406 A1 EP1784406 A1 EP 1784406A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- halogen
- alkyl
- pseudohalogen
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to novel dihydropteridinones of the general formula (1)
- radicals R 1 to R 5 , R a to R c , W, Q 1 and Q 2 have the meanings mentioned in the claims and the description, their isomers, processes for preparing these dihydropteridinones and their use as medicaments.
- Pteridinone derivatives are known as active ingredients with antiproliferative action from the prior art.
- WO 01/019825 and WO 03/020722 describe the use of pteridinone derivatives for the treatment of tumor diseases.
- Tumor cells partially or completely elude regulation and control by the organism and are characterized by uncontrolled growth. This is based on
- cyclin-dependent kinases CDK's
- Aurora B is described as having an essential function in entering mitosis. Aurora B phosphorylates histone H3 on SerlO and thus initiates chromosome condensation (Hsu et al., 2000, Cell 102: 279-91).
- a specific cell cycle arrest in the G2 / M phase can also be triggered, for example, by inhibition of specific phosphatases such as, for example, Cdc25C (Russell and Nurse 1986, Cell 45: 145-53).
- Yeasts with defective Cdc25 gene arrest in the G2 phase while overexpression of Cdc25 leads to premature entry into the mitotic phase (Russell and Nurse 1987, Cell 49: 559-67). Furthermore, arrest in the G2 / M phase may also be due to inhibition of certain motor proteins, the so-called kinesins such as Eg5 (Mayer et al., 1999, Science 286: 971-4), or microtubule stabilizing or destabilizing agents (eg, colchicine, Taxol, etoposide, vinblastine, vincristine) (Schiff and Horwitz 1980, Proc Natl Acad Sci. USA 77: 1561-5).
- Eg5 Mayer et al., 1999, Science 286: 971-4
- microtubule stabilizing or destabilizing agents eg, colchicine, Taxol, etoposide, vinblastine, vincristine
- polo-like kinases In addition to cyclin-dependent and Aurora kinases, the so-called polo-like kinases, a small family of serine / threonine kinases, play an important role in the regulation of the eukaryotic cell cycle. So far, the polo-like kinases PLK-I, PLK-2, PLK-3 and PLK-4 have been described in the literature. Especially for PLK-I a central role in the regulation of the mitosis phase has been shown. PLK-I is responsible for the maturation of the centrosomes, for the activation of the phosphatase Cdc25C, and for the activation of the anaphase Promoting Complex (Glover et al., 1998, Genes Dev.
- compounds of the general formula (I) in which the radicals R 1 to R 5 , R a to R c , W, Q 1 and Q 2 have the meanings mentioned below are inhibitors of specific cell cycle kinases, in particular the polyols. like kinases, act. These compounds exhibit antiproliferative activity by arresting cells in the mitosis phase of the cell cycle before initiating the programmed cell death in the arrested cells.
- the compounds of the present invention can be used to treat diseases related to the activity of specific cell cycle kinases and characterized by excessive or abnormal cell proliferation.
- the present invention therefore relates to compounds of the general formula (1)
- R 1 , R 2 are each independently hydrogen or optionally mono- or polysubstituted C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, or R 1 and R 2 together represent a saturated or partially unsaturated 2-5-membered Form an alkyl bridge in which a -CH 2 group can be replaced by O, S, -NR 8 or a -CH group by N;
- R 4 is a radical selected from the group consisting of hydrogen, -CN, hydroxy, halogen, -OR 8 and -NR 6 R 7 , or a radical selected from the group consisting of optionally mono- or polysubstituted C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-5 alkyloxy, C 2-5 alkenyloxy, C 2-5 alkynyloxy, C 1-6 alkylthio, C 1-6 alkylsulfoxo and C 1-6 alkylsulfonyl, wherein the the substituent (s) may be the same or different and are selected from the group consisting of halogen, -NO 2 ,
- Q 1 is a radical selected from the group consisting of optionally mono- or polysubstituted piperidinyl, piperazinyl, homopiperazinyl, pyrrolidinyl, tropenyl, azacycloheptyl and -N (R 8 ) - (
- Q 2 either absent or a radical selected from the group consisting of singly or multiply optionally substituted C 1-16 alkylene, C 2-16 alkenylene, C 2-16 alkynylene, cycloalkyl, aryl, heterocyclyl and heteroaryl wherein the substituent (s ) may be the same or different and are selected from the group consisting of halogen, -NO 2 , R 8 , -OR 8 , -C (O) R 8 , -C (O) OR 8 , -C (O) NR 8 R 9 , -NR 8 R 9 , -NR 8 C (O) R 9 , -NR 8 C (O) OR 9 , -NR 8 C (O) NR 9 R 10 ,
- R 5 is hydrogen or a radical selected from the group consisting of optionally mono- or polysubstituted C 1-16 alkyl, C 2-16 alkenyl, C 2-16 alkynyl,
- R 6 , R 7 are each independently hydrogen or a radical selected from the group consisting of optionally mono- or polysubstituted C 1-16 alkyl, C 2-16 alkenyl, C 2-16 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl wherein the / the substituent (s) may be the same or different and are selected from the group consisting of halogen, -NO 2 , -OR 8 , -C (O) R 8 , -C (O) OR 8 , -C (O) NR 8 R 9 , -NR 8 R 9 , -NR 8 C (O) R 9 , -NR 8 C (O) OR 9 , -NR 8 C (O) NR 9 R 10 , -NR 8 C (O) ONR 9 R 10 , -NR 8 SO 2 R 9 , -NOR 8 R 9 , -SR 8 , -SOR 8 , -SO 2 R 8 , -SO
- R 8 , R 9 and R 10 are each independently hydrogen or a radical selected from the group consisting of optionally substituted C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein the substituent (s) may be the same or different and are selected from the group consisting of halogen, methyl, ethyl, amino, methylamino,
- n 0, 1, 2 or 3 optionally, in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures, and optionally their pharmacologically acceptable acid addition salts.
- One aspect of the invention are compounds of the general formula (1) wherein W is CR 4 .
- R b is a radical selected from the group consisting of hydrogen, -F, -Cl, methyl and ethyl.
- R a and R c are each independently hydrogen or fluorine; or an optionally monosubstituted or polysubstituted radical selected from the group consisting of C 1-2 AlCl y, C 2 alkenyl, C 2 alkylalkyl, C 3-6 cycloalkyl, aryl,
- substituent (s) may be the same or different and are selected from the group consisting of hydrogen, halogen,
- An additional aspect of the invention are compounds of the general formula (1) wherein R a and R c are each independently hydrogen or fluorine.
- R 1 and R 2 are each independently hydrogen or optionally substituted C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, or R 1 and R 2 together form a saturated or partially unsaturated 2-5-membered alkyl bridge in which a -CH 2 - group by O, S, -NR 8 or a -CH group may be replaced by N mean
- R 5 is hydrogen, methyl, ethyl, hydroxy, methoxy, ethoxy, amino, methylamino, dimethylamino, F, Cl, Br, O-propargyl, CN, methylthio, CONH 2 , ethynyl, propynyl, butynyl or allyl.
- One aspect of the invention is the use of compounds of general formula (1) as pharmaceuticals.
- Another aspect of the invention is the use of compounds of general formula (1) as medicaments with antiproliferative activity.
- Another aspect of the invention is the use of compounds of general formula (1) for the manufacture of a medicament for the treatment and / or prevention of diseases selected from the group consisting of cancer, bacterial and viral infections, inflammatory and autoimmune diseases, chemotherapeutic induced alopecia and Mucositis, cardiovascular diseases, nephrological diseases, as well as chronic and acute neurodegenerative diseases.
- diseases selected from the group consisting of cancer, bacterial and viral infections, inflammatory and autoimmune diseases, chemotherapeutic induced alopecia and Mucositis, cardiovascular diseases, nephrological diseases, as well as chronic and acute neurodegenerative diseases.
- An additional aspect of the invention is the use of compounds of general formula (1) for the preparation of a medicament for inhibiting polo-like kinases.
- An essential aspect of the invention is the use of compounds of general formula (1) for the preparation of a medicament for the inhibition of polo-like kinases PLK1.
- An important aspect of the invention is the use of a compound of formula (1) for the manufacture of a medicament for the treatment and / or prevention of tumors based on overexpression of polo-like kinases.
- One aspect of the invention is a method of treating and / or preventing diseases selected from the group consisting of cancer, bacterial and viral infections, inflammatory and autoimmune diseases, chemotherapeutic induced alopecia and mucositis, cardiovascular diseases, nephrological diseases, and chronic and acute neurodegenerative diseases Diseases, characterized in that an effective amount of a compound of the general formula (1) is administered to a patient.
- compositions containing as active ingredient one or more compounds of general formula (1), optionally in combination with customary auxiliaries and / or carriers.
- alkyl substituents are meant in each case saturated, straight-chain or branched aliphatic hydrocarbon radicals (alkyl radical).
- alkenyl substituents are each straight-chain or branched, unsaturated alkyl radicals which have at least one double bond.
- Alkynyl substituents are to be understood as meaning in each case straight-chain or branched, unsaturated alkyl radicals which have at least one triple bond.
- Haloalkyl refers to alkyl radicals in which one or more hydrogen atoms are replaced by halogen atoms.
- Halogen refers to fluorine, chlorine, bromine and / or iodine atoms.
- Cycloalkyl is a monocyclic or bicyclic ring, it being possible for the ring system to be a saturated ring but also an unsaturated, nonaromatic ring which may optionally also contain double bonds, for example cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, Cyclohexyl, cyclohexenyl, norbornyl, norbornenyl, spiro [5.5] undecane, spiro [5.4] decane and spiro [4.4] nonane.
- Aryl refers to monocyclic or bicyclic rings of 6-12 carbon atoms such as phenyl and naphthyl.
- Heteroaryl is to be understood as meaning monocyclic or bicyclic rings which, instead of one or more carbon atoms, contain one or more identical or different heteroatoms, such as e.g. Nitrogen, sulfur or oxygen atoms.
- heteroatoms such as e.g. Nitrogen, sulfur or oxygen atoms.
- Examples which may be mentioned are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl and triazinyl.
- bicyclic heteroaryl radicals are indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl and benzotriazinyl, indolizinyl,
- Heterocyclyl refers to saturated or unsaturated, non-aromatic, mono-, bicyclic, bridged or spirocyclic bicyclic rings containing 5 to 12 carbon atoms, which bear one or more identical or different heteroatoms, such as nitrogen, oxygen or sulfur, instead of one or more carbon atoms.
- heterocyclyl groups are tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, Isoindoliny, morpholinyl, thiomorpholinyl, Homomo ⁇ holinyl, homopiperidyl, homopiperazinyl, Thiomo ⁇ holinyl 5-oxide, Thiomo ⁇ holinyl-5 ', 1 S 'dioxide, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, 5 Homothiomo ⁇ holinyl-tetrahydrothienyl, homopiperidinyl,', 1 S'-dioxide, oxazolidinony
- Preperative chromatography For medium-pressure chromatography (MPLC), silica gel from Millipore (designation: Granula Silica Si-60A 35-70 ⁇ m) or C-18 RP silica gel from Macherey Nagel (designation: Polygoprep 100-50 Cl 8) is used.
- MLC medium-pressure chromatography
- C-18 RP silica gel from Macherey Nagel designation: Polygoprep 100-50 Cl 8
- columns from Waters (name: Xterra Prep MS C18, 5 ⁇ M, 30 ⁇ 100 mm or symmetry C18, 5 ⁇ m, 19 ⁇ 100) are used.
- the measurement is carried out in deuterated dimethyl sulfoxide-d6. If other solvents are used, these are explicitly stated in the examples or in the methods.
- the measured values are given on a delta scale in the unit ppm. As a standard, tetramethylsilane is used.
- the measurement is carried out on an Avance 400 (400 MHz NMR spectrometer) from Bruker Biospin GmbH.
- Mass spectroscopy / UV spectrometer These data are generated by means of an HPLC-MS system (high performance liquid chromatography with mass detector) from Agilent.
- the system is constructed in such a way that following the chromatography (column: Zorbax SB-C8, 3.5 ⁇ m, 2.1x50, Agilent) a diode array detector (G1315B from Agilent) and a mass detector (1100 LS-MSD SL; G1946D; Agilent) are connected in series.
- the plant is operated with a flow of 0.6 ml / min.
- a gradient is run through within 3.5 minutes (initial gradient: 95% water and 5% acetonitrile; gradient end: 5% water and 95% acetonitrile, the two solvents each being admixed with 0.1% formic acid).
- the compounds according to the invention can be prepared by the synthesis processes A to C described below, the substituents of the general formulas (I) to (VI) having the abovementioned meanings. These methods are to be understood as an explanation of the invention without limiting the same to their subject matter.
- Intermediate III is prepared by substitution of a leaving group LG, for example halogen, SCN, methoxy, preferably chlorine or fluorine, on an aromatic system I by a nucleophile II.
- LG for example halogen, SCN, methoxy, preferably chlorine or fluorine
- a solvent for example 1,4-dioxane, tetrahydrofuran, N, N-dimethylformamide, JV-methyl-2-pyrrolidinone or JV, JV-dimethylacetamide touched.
- a base for example potassium carbonate, sodium carbonate, cesium carbonate, N-ethyl-N, N-diisopropylamine or triethylamine are added.
- the reaction mixture is further stirred at a temperature of 50 to 100 ° C for 12 to 72 h. Thereafter, the solvent is distilled off and the residue is purified by chromatography.
- the compound III is dissolved in a solvent, for example, methanol, ethanol, ethyl acetate, tetrahydrofuran or acetone.
- a catalyst is added, for example palladium on carbon, palladium hydroxide or Rainey nickel. This suspension is transferred to an autoclave. This is subjected to a hydrogen pressure of 2 to 10 bar. The mixture is stirred for 1 to 10 days at 20-40 ° C. Subsequently, the catalyst is filtered off and the solvent removed in vacuo.
- a solvent for example, methanol, ethanol, ethyl acetate, tetrahydrofuran or acetone.
- a catalyst is added, for example palladium on carbon, palladium hydroxide or Rainey nickel. This suspension is transferred to an autoclave. This is subjected to a hydrogen pressure of 2 to 10 bar. The mixture is stirred for 1 to 10 days at 20-40 ° C. Subsequently, the catalyst is filtered off and the solvent
- the preparation of the end compound VI is effected by substitution of a leaving group LG, for example halogen, SCN, methoxy, preferably chlorine, on a heteroaromatic system V by a nucleophile IV.
- LG for example halogen, SCN, methoxy, preferably chlorine
- End point consists of 5% water and 95% acetonitrile.
- the crude product is purified by column chromatography.
- the carrier material used is C18-RP gel and a gradient is passed through which consists of 95% water and 5% acetonitrile at the starting point and 5% water and 95% acetonitrile at the end point.
- the compounds of the general formula (I) are distinguished by a variety of possible uses in the therapeutic field. Worth mentioning are those applications for which the inhibition of specific cell cycle kinases, in particular the inhibitory effect on the proliferation of cultured human tumor cells, but also on the proliferation of other cells, such as. Endothelial cells play a role.
- the proliferation inhibition afforded by the compounds of this invention is mediated by arrest of the cells, especially in the G2 / M phase of the cell cycle.
- the cells arrest for a certain period of time in this cell cycle phase, depending on the cells used, before the programmed cell death is initiated.
- Arrest in the G2 / M phase of the cell cycle is e.g. triggered by the inhibition of specific cell cycle kinases.
- the compounds of the general formula I according to the invention, their isomers and their physiologically tolerable salts are suitable for the treatment of diseases which are characterized by excessive or abnormal cell proliferation.
- Such diseases include, for example: viral infections (eg HIV and Kaposi sarcoma); Inflammation and autoimmune diseases (eg, colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and / or parasitic infections; Leukemia, lymphoma and solid tumors; Skin disorders (eg psoriasis); Bone diseases; cardiovascular diseases (eg restenosis and hypertrophy). Further, they are useful as protection of proliferating cells (eg, hair, intestinal, blood and progenitor cells) against DNA damage by radiation, UV treatment and / or cytostatic treatment (Davis et al., 2001).
- viral infections eg HIV and Kaposi sarcoma
- Inflammation and autoimmune diseases eg, colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing
- bacterial, fungal and / or parasitic infections eg, colitis, arthritis, Alzheimer's disease, glomerulonephritis
- novel compounds can be used for the prevention, short-term or long-term treatment of the abovementioned diseases, also in combination with other active substances which are used for the same indications, for example cytostatics, hormones or antibodies.
- the effect of the compounds according to the invention was determined in the PLK1 inhibition assay, in the cytotoxicity test on cultured human tumor cells and / or in a FACS analysis, for example on HeLa S3 cells.
- the compounds showed a good to very good activity in both test methods, ie, for example, an EC 50 value in the HeLa S3 cytotoxicity test of less than 5 ⁇ mol / L, generally less than 1 ⁇ mol / L and an IC 50 value in the PLK1 inhibition assay smaller 1 ⁇ mol / L.
- Recombinant human and at its N-terminal end linked to GST PLK1 enzyme is isolated from baculovirus-infected insect cells (Sf21). The purification is carried out by affinity chromatography on glutathione Sepharose columns.
- the number of cells is determined, the cells are centrifuged off (5 minutes, 4 ° C., 800 rpm) and 1 ⁇ with PBS (8 g NaCM, 0.2 g KCl / l, 1.44 g Na 2 HPO 4 / l, 0.24 g KH 2 PO4 / 1). After centrifuging again, the pellet is frozen in liquid nitrogen shock.
- the pellet is thawed rapidly and poured into ice-cold lysis buffer (50 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 5 ⁇ g / ml leupeptin, 5 ⁇ g / ml aprotinin, 100 ⁇ M NaF, 100 ⁇ M PMSF, 10 mM ⁇ -glycerol phosphate, 0.1 mM Na 3 VO 4 , 30 mM 4-nitrophenylphosphate) to IxIO 8 cells / 17.5 ml. The cells are lysed for 30 minutes on ice.
- ice-cold lysis buffer 50 mM HEPES pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 5 ⁇ g / ml leupeptin, 5 ⁇ g / ml aprotinin, 100 ⁇ M NaF, 100 ⁇ M PMSF, 10 mM ⁇ -glyce
- the clear supernatant is mixed with glutathione Sepharosebeads (1 ml resuspended and washed Beads for 50 ml of supernatant) and incubated for 30 minutes at 4 ° C on a rotating board.
- the protein concentration is determined by Bradford assay.
- the reaction is started and carried out for 45 minutes at 30 ° C with gentle shaking (650 rpm on IKA shaker MTS2).
- the reaction is stopped by addition of 125 ⁇ l of ice-cold 5% TCA per well and incubated on ice for at least 30 minutes.
- the preciptitate is transferred by harvesting to filter plates (96-well microtiter filter plate: UniFilter-96, GF / B, Packard, No. 6005177), then washed four times with 1% TCA and dried at 60 ° C.
- the slab is sealed with sealing tape and the precipitated amount of P33 is measured with the Wallac Betacounter.
- the measured data are evaluated with the standard Graphpad software (Levenburg-Marquard Algorithm). Measurement of cytotoxicity on cultured human tumor cells
- cells of the cervical carcinoma tumor cell line HeLa S3 obtained from American Type Culture Collection (ATCC) were cultured in Ham's F12 medium (Life Technologies) and 10% fetal bovine serum (Life Technologies) and tested in the log growth phase harvested.
- the HeLa S3 cells were then introduced into 96-well plates (Costar) with a density of 1000 cells per well and incubated overnight in an incubator (at 37 ° C. and 5% CO 2 ), with 6 wells on each plate only with Medium were filled (3 wells for medium control, 3 wells for incubation with reduced AlamarBlue reagent).
- the active substances were added to the cells in different concentrations (dissolved in DMSO; final DMSO concentration: 0.1%) (in triplicate in each case). After 72 hours of incubation, 20 ⁇ l of AlamarBlue reagent (AccuMed International) were added to each well and the cells were incubated for a further 7 hours.
- AlamarBlue reagent 20 ⁇ l of reduced AlamarBlue reagent were added to 3 wells (AlamarBlue reagent, which was autoclaved for 30 min). After 7 h of incubation, the color conversion of the AlamarBlue reagent in the individual wells was determined in a Perkin Elmer fluorescence spectrophotometer (Exitation 530 nm, emission 590 nm, Slits 15, Integrate time 0.1). The amount of reacted AlamarBlue reagent represents the metabolic activity of the cells. The relative cell activity was calculated as a percentage of the control (HeLa S3 cells without inhibitor) and the drug concentration, which inhibits the cell activity to 50% (IC 50 ) derived. The values were calculated from the average of three individual determinations - with correction of the blank value (medium control).
- PI Propidium iodide
- PI Propidium iodide
- stoichiometrically binds to double-stranded DNA, and is thus capable of determining the proportion of cells in the Gl, S, and G2 / M phase of the cell cycle based on the cellular DNA content.
- Cells in the GO and Gl phases have a diploid DNA content (2N), while cells in G2 or mitosis have a 4N DNA content.
- 2N diploid DNA content
- G2 or mitosis have a 4N DNA content.
- PI staining for example, 0.4 ml HeLa S3 cells were seeded onto a 75 cm 2 cell culture flask, after 24 h either 0.1% DMSO was added as a control or the substance was added in various concentrations (in 0.1% DMSO).
- the cells were incubated with the substance or with DMSO for 24 h before the cells were washed twice with PBS and then with trypsin / EDTA.
- the cells were centrifuged (1000 rpm, 5 min, 4 ° C) and the cell pellet washed twice with PBS before the cells were resuspended in 0.1 ml PBS. Subsequently, the cells were fixed for 16 hours at 4 ° C or alternatively for 2 hours at -20 ° C with 80% ethanol.
- the fixed cells (10 6 cells) were centrifuged (1000 rpm, 5 min, 4 ° C), washed with PBS and then centrifuged again.
- the cell pellet was resuspended in 2 ml of Triton X-100 in 0.25% PBS and incubated on ice for 5 min before 5 ml of PBS was added and centrifuged again.
- the cell pellet was resuspended in 350 ⁇ l PI staining solution (0.1 mg / ml RNase A, 10 ⁇ g / ml prodidium iodide in 1 ⁇ PBS).
- the cells were incubated with the staining buffer for 20 min in the dark before being transferred to sample vials for the FACS scan.
- the DNA measurement was carried out in a Becton Dickinson FACS Analyzer, with an argon laser (500 mW, emission 488 nm), and the DNA Cell Quest program (BD).
- the logarithmic PI fluorescence was determined with a band-pass filter (BP 585/42).
- the quantification of the cell populations in the individual cell cycle phases was carried out with the ModFit LT program of Becton Dickinson.
- compounds of the invention were tested on additional tumor cells.
- these compounds are based on carcinomas of various tissues (eg, breast (MCF7), colon (HCT16), head and neck (FaDu), lung (NCI-H460), pancreas (BxPC-3), prostate (DU145)).
- Sarcomas eg, SK-UT-IB
- leukemias and lymphomas eg, HL-60, Jurkat, THP-I
- other tumors eg, melanoma (BRO), gliomas (U-87MG )
- This demonstrates the broad applicability of the compounds according to the invention for the treatment of a wide variety of tumor types.
- the compounds of the general formula (I) can be used alone or in combination with other active compounds according to the invention, if appropriate also in combination with other pharmacologically active substances.
- Suitable application forms are, for example, tablets, capsules, suppositories, solutions, in particular solutions for injection (s.c., i.V., i.m.) and infusion, juices, emulsions or dispersible powders.
- the proportion of the pharmaceutically active compound (s) in each case in the range of 0.1 to 90 wt .-%, preferably 0.5 to 50 wt .-% of the total composition, i. in amounts sufficient to reach the dosage range given below.
- the said doses may, if necessary, be given several times a day.
- Corresponding tablets can be prepared, for example, by mixing the active substance (s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants, such as
- Magnesium stearate or talc, and / or agents for obtaining the depot effect, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate are obtained.
- the tablets can also consist of several layers.
- Coated tablets can accordingly be produced by coating cores produced analogously to the tablets with agents customarily used in tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar.
- the core can also consist of several layers.
- the dragee sheath to achieve a depot effect of several layers may consist of the above mentioned in the tablets excipients can be used.
- Juices of the active compounds or active compound combinations according to the invention may additionally contain a sweetener, such as saccharin, cyclamate, glycerol or sugar, and a taste-improving agent, for example flavorings, such as vanillin or orange extract.
- a sweetener such as saccharin, cyclamate, glycerol or sugar
- a taste-improving agent for example flavorings, such as vanillin or orange extract.
- Injection and infusion solutions are prepared in a conventional manner, e.g. with the addition of isotonic agents, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, if appropriate using emulsifiers and / or dispersants, wherein, for example, when using water as a diluent organic solvents may optionally be used as solubilizers or auxiliary solvents , manufactured and filled into injection vials or ampoules or infusion bottles.
- isotonic agents e.g. with the addition of isotonic agents, preservatives, such as p-hydroxybenzoates, or stabilizers, such as alkali metal salts of ethylenediaminetetraacetic acid, if appropriate using emulsifiers and / or dispersants, wherein, for example, when using water as a diluent organic solvents may optionally be used as solubilizer
- the capsules containing one or more active ingredients or combinations of active substances can be prepared, for example, by mixing the active ingredients with inert carriers, such as lactose or sorbitol, and encapsulating them in gelatine capsules.
- inert carriers such as lactose or sorbitol
- Suitable suppositories can be prepared, for example, by mixing with suitable carriers, such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats or polyethylene glycol or its derivatives.
- suitable carriers such as neutral fats
- ground natural minerals eg kaolins, clays, talc, chalk
- ground synthetic minerals eg fumed silica and silicates
- sugars eg pipe, milk and dextrose
- emulsifiers eg lignin, liquors, methylcellulose, starch and polyvinylpyrrolidone
- lubricants eg Magnesium stearate, talc, stearic acid and sodium lauryl sulfate.
- the application is carried out in a customary manner, preferably orally or transdermally, particularly preferably orally.
- the tablets may, of course, besides the abovementioned excipients also additives, such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives, such as starch, preferably potato starch, gelatin and the like. Further, lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for tableting.
- the active ingredients may be added to the abovementioned excipients with various flavor enhancers or dyes.
- solutions of the active ingredients may be employed using suitable liquid carrier materials.
- the dosage for intravenous use is 1 - 1000 mg per hour, preferably between 5 - 500 mg per hour.
- the finely ground active substance, lactose and part of the corn starch are mixed together.
- the mixture is sieved, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet granulated and dried.
- the granules, the remainder of the corn starch and the magnesium stearate are sieved and mixed together.
- the mixture is compressed into tablets of suitable shape and size.
- the active ingredient is dissolved in water at its own pH or optionally at pH 5.5-6.5 and treated with sodium chloride as isotonan.
- the resulting solution is filtered pyrogen-free and the filtrate filled under aseptic conditions in ampoules, which are then sterilized and sealed.
- the vials contain 5 mg, 25 mg and 50 mg active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne de nouvelles dihydroptéridinones de formule générale (I), et leurs isomères. Dans ladite formule (I), les radicaux R1 à R5, Ra à Rc, W, Q1 et Q2 sont tels que définis dans les revendications et la description. Cette invention concerne également l'utilisation desdits composés pour produire un médicament servant à traiter des maladies qui sont caractérisées par une prolifération cellulaire excessive ou anormale.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05779168A EP1784406A1 (fr) | 2004-08-27 | 2005-08-19 | Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04020339 | 2004-08-27 | ||
PCT/EP2005/054099 WO2006021548A1 (fr) | 2004-08-27 | 2005-08-19 | Dihydropteridinones, leur procede de production, et leur utilisation en tant que medicaments |
EP05779168A EP1784406A1 (fr) | 2004-08-27 | 2005-08-19 | Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1784406A1 true EP1784406A1 (fr) | 2007-05-16 |
Family
ID=34926318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05779168A Withdrawn EP1784406A1 (fr) | 2004-08-27 | 2005-08-19 | Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments |
Country Status (5)
Country | Link |
---|---|
US (1) | US7371753B2 (fr) |
EP (1) | EP1784406A1 (fr) |
JP (1) | JP2008510771A (fr) |
CA (1) | CA2578560A1 (fr) |
WO (1) | WO2006021548A1 (fr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
EP1630163A1 (fr) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments |
EP1632493A1 (fr) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
EP2223925A1 (fr) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
MX2009003793A (es) | 2006-10-09 | 2009-12-14 | Takeda Pharmaceutical | Inhibidores de cinasa. |
EP2090577B1 (fr) | 2006-10-19 | 2017-04-05 | Signal Pharmaceuticals, LLC | Composés héteroaryliques, compositions les contenant et leur utilisation en tant qu'inhibiteurs de protein kinases |
GB0621203D0 (en) * | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
KR20090071668A (ko) * | 2006-10-25 | 2009-07-01 | 크로마 데러퓨릭스 리미티드 | 암치료에 유용한 폴로형 키나아제 억제제로서 프테리딘 유도체 |
TW200902012A (en) * | 2007-05-16 | 2009-01-16 | Lilly Co Eli | Triazolyl aminopyrimidine compounds |
US8329695B2 (en) * | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
GEP20125704B (en) * | 2007-09-25 | 2012-12-10 | Takeda Pharmaceuticals Co | Plk kinase inhibitors |
WO2009067547A1 (fr) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase de type polo |
EP2215091B1 (fr) | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase |
EP2100894A1 (fr) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase) |
EP2112152A1 (fr) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones comme inhibiteurs Plk |
GB0807451D0 (en) * | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | Inhibitors of PLK |
WO2010025073A1 (fr) * | 2008-08-28 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Dihydroimidazo [ 1, 5-f] ptéridines en tant qu'inhibiteurs de kinases de type polo (plk) |
EP2325185A1 (fr) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Inhibiteur de Plk |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
JP5931933B2 (ja) | 2011-02-25 | 2016-06-08 | 武田薬品工業株式会社 | N−置換オキサジノプテリジンおよびオキサジノプテリジノン |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
US9006226B2 (en) | 2012-02-23 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Dihydropteridinones I |
TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
EP2958918B1 (fr) * | 2013-02-21 | 2016-12-07 | Boehringer Ingelheim International GmbH | Dihydroptéridinones ii |
WO2014127815A1 (fr) * | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim International Gmbh | Dihydroptéridinones i |
WO2015011084A1 (fr) * | 2013-07-23 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Dihydropyrido[3,4-b]pyrazinones substitués en tant qu'inhibiteurs mixtes des protéines bet et des polo-like kinases |
RU2016105108A (ru) | 2013-07-25 | 2017-08-30 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ингибиторы факторов транскрипции и их применение |
US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
UY35945A (es) | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
WO2015117087A1 (fr) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Utilisations des dérivés de diazépane |
RU2673944C2 (ru) * | 2014-01-31 | 2018-12-03 | Дана-Фарбер Кансер Институт, Инк. | Дигидроптеридиноновые производные и их применения |
WO2015193228A1 (fr) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 1,4-dihydropyrido[3,4-b]pyrazinones inhibitrices de protéine bet, à groupe éther ou amino aromatique para-substitué |
EP3177626A4 (fr) | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Dérivés de diazépane et leurs utilisations |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
JP2018526421A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | シアノチエノトリアゾロジアゼピンおよびこれらの使用 |
AU2016361478B2 (en) | 2015-11-25 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibitors and uses thereof |
DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0202713A3 (en) * | 1999-09-15 | 2005-02-28 | Warner Lambert Co | Pteridinones as kinase inhibitors |
DE50207522D1 (de) * | 2001-09-04 | 2006-08-24 | Boehringer Ingelheim Int | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
AU2003215591B2 (en) * | 2003-02-26 | 2010-06-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Dihydropteridinones, method for the production and use thereof in the form of drugs |
-
2005
- 2005-08-19 EP EP05779168A patent/EP1784406A1/fr not_active Withdrawn
- 2005-08-19 CA CA002578560A patent/CA2578560A1/fr not_active Abandoned
- 2005-08-19 WO PCT/EP2005/054099 patent/WO2006021548A1/fr active Application Filing
- 2005-08-19 JP JP2007528834A patent/JP2008510771A/ja active Pending
- 2005-08-25 US US11/211,783 patent/US7371753B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2006021548A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2008510771A (ja) | 2008-04-10 |
WO2006021548A1 (fr) | 2006-03-02 |
US7371753B2 (en) | 2008-05-13 |
US20060046990A1 (en) | 2006-03-02 |
CA2578560A1 (fr) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1784406A1 (fr) | Dihydrpteridinones, procédés de préparation et leur utilisation en tant que médicaments | |
EP1776363B1 (fr) | Nouvelles 6-formyltetrahydropteridines, procede de production et utilisation de ces dernieres comme medicaments, notamment contre le cancer | |
EP1761536B1 (fr) | Nouveaux 2-benzylaminodihydropteridinones, procede de production associe et leur utilisation en tant que medicaments | |
EP1768981B1 (fr) | Nouveaux pyridodihydropyrazinones, procede de production et utilisation de ces derniers comme medicaments | |
EP1786817A1 (fr) | Pteridinones en tant que inhibiteurs de plk (polo like kinase) | |
EP1781640B1 (fr) | Dérivés de 2,4-di(aminophényl)pyrimidine comme inhibiteurs de plk | |
EP1786819B1 (fr) | Derives de dihydropteridinone, procedes pour les produire et utilisation de ceux-ci comme medicaments | |
EP1427730B1 (fr) | Nouvelles dihydropteridinones, procedes pour les produire et leur utilisation en tant que medicaments | |
EP1599478B1 (fr) | Dihydropteridinones, prodede de production et utilisation de ces dernieres comme medicaments | |
EP1786818A1 (fr) | Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament | |
EP1751118B1 (fr) | Pyrimidines comme inhibiteurs de plk | |
EP0645390A1 (fr) | Pyrimido 5,4-d pyrimidines trisubstitués pour moduler la résistance multidrogue, médicaments les contenant et procédés pour leur préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070327 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20080520 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110121 |